Paradigm Medical Industries, Inc.

Paradigm Medical Industries, Inc.

PDMI
Paradigm Medical Industries, Inc.US flagOther OTC
0.00
USD
- -
- -
324,879.00Market Cap
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
TTM
Revenue per Share
7,564.78
6,922.88
5,981.12
3,027.64
1,271.93
1,205.51
523.67
125.41
70.71
11.05
0.08
0.02
- -
2
Basic EPS, GAAP
-4,788.46
-8,063.26
-7,898.04
-6,291.6
-1,426.61
3.94
-1,282.18
-103.75
-62.06
-15.17
-0.08
-0.02
- -
-2.48
Free Cash Flow per Basic Share
-3,739.88
-5,231.37
-6,811.93
-1,584.88
-294.8
-187.8
-634.78
-47.31
-42.87
-4.42
-0.04
-0.03
- -
-0.5
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-20,647.77
-28,028.6
-32,089.12
-30,250.42
-23,614.14
-22,355.12
-14,775.16
-3,645.66
-2,281.53
-545.15
-5.5
-1.33
- -
-104.92
Tangible Book Value per Share
5,668.02
6,353.55
6,429
1,092.5
-1.66
3.54
-440.88
-129.41
-95.8
-35.96
-0.32
-0.06
- -
-6.68
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11
46
- -
1
Sales/Revenue/Turnover
7
8
8
5
3
3
2
2
2
1
1
1
1
1
Operating Margin (%)
-63.01
-118.21
-117.25
-207.13
-116.9
-12.8
-99.05
-32.39
-62.29
-89.12
-60.84
-114.88
-42.75
-73.6
Depreciation Expense
- -
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-5
-9
-10
-11
-3
- -
-5
-2
-2
-2
-1
-1
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-63.3
-116.47
-128.08
-207.81
-103.33
2.09
-244.84
-82.73
-87.77
-137.33
-110.72
-133.33
-61.4
-124.03
Working Capital
5
7
8
2
- -
- -
- -
- -
- -
-2
-1
-1
-2
-2
LT Debt
- -
- -
- -
- -
- -
- -
2
3
2
2
3
2
1
2
Total Equity
6
9
10
3
1
1
-2
-2
-2
-4
-3
-2
-3
-4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-50.65
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-0.11
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'08
Dec'08
Mar'09
ST Debt
- -
2
- -
LT Borrowings
4
2
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
5
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Sep'08
Dec'08
Mar'09
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
1
3
3
Payables & Accruals
1
1
3
ST Debt
- -
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-38.73%
10%
4.2%
Free Cash Flow
29.83%
16.86%
-38.79%
Net Income, GAAP
-884.88%
-19.7%
-51.03%
Sales/Revenue/Turnover
-19.19%
-17.67%
6.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
1
2010
- -
- -
- -
- -
1
2011
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
-0.18
- -
- -
- -
-0.08
2010
- -
- -
- -
- -
-0.02
2011
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Charles S. Pritchard
Full Time Employees
5
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
4273 South 590 West Salt Lake City UT United States of America 84123
IPO Date
Jul 22, 1996
Business
Paradigm Medical Industries, Inc. is dedicated to the creation, production, distribution, and commercialization of sophisticated medical devices aimed at the prompt identification of glaucoma and various other conditions affecting the eye across the United States. The company’s extensive product portfolio encompasses a range of biometric analyzer A-scans, including the P-2000 and P-2500 models, alongside P-2500 A-scan/pachymeters and standalone P2200 pachymeters for precise measurements. They also provide P2700 A/B and P37-II A/B scans for detailed ocular imaging, in addition to advanced blood flow analyzers crucial for detecting and managing glaucoma and other disorders related to retinal vasculature. Visual field testing is supported by their LD 500 and LD700 autoperimeters. Furthermore, the company offers corneal topographers such as the PARAVUE 300 for diagnostic purposes and contact lens fitting, alongside the SURVEYOR 500 for comprehensive cornea and anterior segment analysis. Their diagnostic tools extend to PARAMAX, which assesses ganglion cell functionality to pinpoint potential glaucoma cases, along with P60 and P60 ACI ultrasound biomicroscopes, and the PARACAM 1000, a non-contact endothelial microscope. Complementing these instruments are essential software solutions and accessories. The enterprise was established in 1989 and maintains its operational base in Salt Lake City, Utah.

Company News

APIChat
  • Edap Tms (NASDAQ:EDAP) vs. Paradigm Medical Industries (OTCMKTS:PDMI) Head-To-Head Analysis